Andrew G Robinson

7PUBLICATIONS
38CO-AUTHORS
Liquid biopsiesPredictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 11, 2023
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2.

Dwight H Owen, Navneet Singh, Nofisat Ismaila

|Feb 03, 2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

Silvia Novello, Dariusz M Kowalski, Alexander Luft

|Dec 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.

Dwight H Owen, Navneet Singh, Nofisat Ismaila

|Dec 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.

Dwight H Owen, Navneet Singh, Nofisat Ismaila

|Apr 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson

|Feb 16, 2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

Nasser H Hanna, Andrew G Robinson, Sarah Temin

Pageof 2